Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2016.

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Convergence: What's Next at the Nexus?, features profiles of Direct-Haler, EndoBionics, Polymerix and X-Cell Medical. Plus these Start-Ups across Health Care: Discovery Genomics, FoldRx and Neuronetics.

Discovery Genomics Inc.'s Sleeping Beauty transposon vector is non-viral, but it can integrate into the genome to achieve long-term expression. DGI uses it in two parts: the transposon vector carries the therapeutic genes, and the transposase enzyme moves it from the vector into the chromosome. When delivered to cells at the same time, the transposase cuts the therapeutic gene out of the vector and inserts it into the host chromosome, much like you cut and paste using a word processor.

Summarizing the month in European dealmaking.